Abstracts tagged "Gene Expression"

Abstract Number: 2873 • 2017 ACR/ARHP Annual Meeting
DNA Microarray Analysis Identifies Nuclear Receptor Subfamily 4 Group a Member 2 (NR4A2) As a Novel Molecule Involved in the Pathogenesis of Sjogren’s Syndrome
Hiroyuki Takahashi, Hiroto Tsuboi, Hiromitsu Asashima, Hanae Kudo, Yuko Ono, Saori Abe, Yuya Kondo, Isao Matsumoto and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose:Some reports on DNA microarray analysis in labial salivary glands (LSGs) of Sjögren’s syndrome (SS) and healthy controls (HCs) showed that the genes associated with…
Abstract Number: 756 • 2017 ACR/ARHP Annual Meeting
Novel Machine Learning Classifier Accurately Predicts Intrinsic Molecular Subsets for Patients with Systemic Sclerosis
Jennifer Franks¹, Viktor Martyanov¹, Guoshuai Cai¹ and Michael L. Whitfield², ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: High-throughput gene expression profiling of skin biopsies from patients with systemic sclerosis (SSc) has identified four “intrinsic” gene expression subsets conserved across multiple cohorts…
Abstract Number: 1707 • 2017 ACR/ARHP Annual Meeting
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Viktor Martyanov¹, Yolanda Nesbeth², Guoshuai Cai¹, Tammara A. Wood¹, Jake Reder², Scott Constantine³, Barbara White³, Robert F. Spiera⁴ and Michael L. Whitfield¹, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Celdara Medical, LLC, Lebanon, NH, ³Corbus Pharmaceuticals, Inc., Norwood, MA, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Anabasum (JBT-101) is a non-immunosuppressive, synthetic, CB2 agonist that resolves inflammation and fibrosis in animal models of SSc and reduces TGF-β and collagen production…
Abstract Number: 2885 • 2017 ACR/ARHP Annual Meeting
Tadalafil Reduces Skin Fibrosis and Profibrotic Genes Expression in Patients with Systemic Sclerosis
Sakir Ahmed, Mohit Kumar Rai, Durga Prasanna Misra and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Currently, drugs that modify skin fibrosis in Systemic Sclerosis (SSc) have efficacy in certain subgroups of patients only. Phosphodiesterase-5 inhibitors (PDE5i) are known to…
Abstract Number: 764 • 2017 ACR/ARHP Annual Meeting
Application of a Novel Computational Approach to Identify New Targets and Pathways for Therapeutic Intervention in Scleroderma
Elma Kurtagic, Joel Pradines, Anthony Manning and Ishan Capila, Research, Momenta Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Systemic Sclerosis (SSc) is a complex autoimmune disease with chronic progressive course and high interpatient variability. It is characterized by inflammation, vascular dysfunction and…
Abstract Number: 1922 • 2017 ACR/ARHP Annual Meeting
Cell Type Specific Gene Expression Analysis of Early Systemic Sclerosis Skin Shows a Prominent Activation Pattern of Innate and Adaptive Immune System in the Prospective Registry for Early Systemic Sclerosis (PRESS) Cohort
Shervin Assassi¹, Dinesh Khanna², Monique Hinchcliff³, Virginia D. Steen⁴, Faye Hant⁵, Jessica K. Gordon⁶, Ami A. Shah⁷, Jun Ying⁸, William Swindell⁹, Wenjin Zheng¹⁰, Lisha Zhu¹⁰, Victoria K. Shanmugam¹¹, Robyn T. Domsic¹², Flavia V. Castelino¹³, Elana J. Bernstein¹⁴ and Tracy M. Frech¹⁵, ¹University of Texas McGovern Medical School, Houston, TX, ²University of Michigan, Ann Arbor, MI, ³Rheumatology, Northwestern Medicine, Chicago, IL, ⁴Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Department of Internal Medicine - Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Dermatology, University of Michigan - Ann Arbor, Ann Arbor, MI, ¹⁰University of Texas - School of Biomedical Informatics, Houston, TX, ¹¹Rheumatology, The George Washington University, Washington, DC, ¹²Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹³Rheumatology, Harvard Medical School, Boston, MA, ¹⁴Rheumatology, Columbia University, New York, NY, ¹⁵Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: To examine the global gene expression profile in patients with very early diffuse systemic sclerosis (SSc). Methods: Skin biopsies were obtained from patients enrolled…
Abstract Number: 2897 • 2017 ACR/ARHP Annual Meeting
A Non-Coding Genetic Variant Maximally Associated with Serum Urate Levels Is Functionally Linked to HNF4A-Dependent PDZK1 Expression
Tony R. Merriman¹, Sarada Ketharnathan², James Boocock³, Amanda Phipps-Green², Jisha Antony², Megan Leaask², Justin O'Sullivan⁴ and Julia Horsfield², ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of California Los Angeles, Los Angeles, CA, ⁴University of Auckland, Auckland, New Zealand
A non-coding genetic variant maximally associated with serum urate levels is functionally linked to HNF4A-dependent PDZK1 expressionBackground/Purpose: Genome-wide association studies have revealed several dozen genetic…
Abstract Number: 770 • 2017 ACR/ARHP Annual Meeting
Integrating Analysis of Skin RNA in Situ Hybridization Using Rnascope and Whole Skin Gene Expression in Systemic Sclerosis Skin to Localize Key Pathogenic Drivers of Skin Fibrosis
Corrado Campochiaro¹, Emma C. Derrett-Smith¹, Voon H. Ong², Gail Pearse³, Katherine Nevin³, Shaun Flint³, Mary Morse³, Nicolas Wisniacki⁴ and Christopher Denton⁵, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³GlaxoSmithKline, Stevenage, United Kingdom, ⁴ImmunoImflammation, GlaxoSmithKline, Stevenage, United Kingdom, ⁵Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom
Background/Purpose: Skin gene expression profiling can distinguish SSc from normal skin and can detect different subsets of disease. Previous studies have reported a cross-sectional relationship…
Abstract Number: 1980 • 2017 ACR/ARHP Annual Meeting
Impact of Whole-Body Cryotherapy on Gene Expression of Peripheral Blood Cells in Patients with Fibromyalgia and Association with Patient-Reported Outcomes
Susanne Drynda¹, Oliver Mika² and Joern Kekow³, ¹University of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ²University of Magdeburg, Clinic of Rheumatology, Gommern, Germany, ³University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany
Background/Purpose: Whole-body cryotherapy (WBCT) has been demonstrated in several studies as being effective in the reduction of inflammatory symptoms and in providing pain relief. It…
Abstract Number: 2977 • 2017 ACR/ARHP Annual Meeting
Molecular Phenotypes Associated with Clinical Disease Activity in Adult Systemic Lupus Erythematosus
Rufei Lu¹, Joel M. Guthridge², Cristina Arriens³, Teresa Aberle⁴, Stan Kamp⁴, Melissa E. Munroe⁴, Tim Gross¹, Wade DeJager⁴, Susan Macwana⁴, Virginia C. Roberts⁴, Stephen Apel⁵, Hua Chen⁴, Eliza Chakravarty^6,7, Katherine Thanou⁴, Joan T. Merrill⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose : Remarkable clinical and pathophysiological diversity complicate diagnosis, treatment and therapeutic development in systemic lupus erythematosus (SLE). This study used molecular phenotyping to identify…
Abstract Number: 137 • 2017 Pediatric Rheumatology Symposium
Chromatin Landscapes and Genetic Risk For Juvenile Idiopathic Arthritis
James Jarvis¹, Lisha Zhu², Lai Ping Wong³, Tao Liu⁴, Kaiyu Jiang³ and Yanmin Chen³, ¹Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY, ²Biochemistry, University at Buffalo, Buffalo, NY, ³Pediatrics, University at Buffalo, Buffalo, NY, ⁴Department of Biochemistry, University at Buffalo, Buffalo, NY
Background/Purpose: The transcriptomes of peripheral blood cells in children with juvenile idiopathic arthritis (JIA) show distinct transcriptional aberrations that suggest impairment of transcriptional regulation. To…
Abstract Number: 8 • 2017 Pediatric Rheumatology Symposium
Examination of Reported Risk Loci from Candidate Gene Studies of Systemic Juvenile Idiopathic Arthritis Identifies Link between IL1RN Variation and both Disease Susceptibility and Response to Interleukin-1 Directed Therapy
Victoria Arthur¹, Emily Shuldiner¹, Anne Hinks², The International Childhood Arthritis Genetics (INCHARGE) Consortium³, Patricia Woo⁴, Wendy Thomson², Elaine F. Remmers⁵ and Michael J. Ombrello¹, ¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³INCHARGE Consortium, Bethesda, MD, ⁴Paediatric Rheumatology Unit, University College London, London, United Kingdom, ⁵Inflammatory Disease Section, NHGRI, NIH, Bethesda, MD
Background/Purpose: Systemic JIA (sJIA) is a childhood inflammatory disease whose pathophysiology is poorly understood. sJIA is phenotypically heterogeneous with variable manifestations and responses to treatment.…
Abstract Number: 128 • 2017 Pediatric Rheumatology Symposium
Treatment Response in Polyarticular Juvenile Idiopathic Arthritis is Associated With Transcriptional Changes and Chromatin Reorganization in CD4+ T cells
Evan Tarbell¹, Kaiyu Jiang², Yanmin Chen², Tao Liu³ and James Jarvis⁴, ¹Biochemistry, University at Buffalo, Buffalo, NY, ²Pediatrics, University at Buffalo, Buffalo, NY, ³Department of Biochemistry, University at Buffalo, Buffalo, NY, ⁴Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: The polyarticular form of JIA is associated with well-documented transcriptional abnormalities in peripheral blood cells. The abnormalities can be observed in neutrophils, peripheral blood…
Abstract Number: 140 • 2017 Pediatric Rheumatology Symposium
Modular Gene Expression Discrimination of Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Subphenotypes in Peripheral Blood
Urko Marigota¹, Angela Mo¹, Jarod Prince², Lai Hin Kimi Chan³, Subramaniam Kugathasan², Greg Gibson¹ and Sampath Prahalad⁴, ¹Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of diseases which have in common inflammatory arthritis, but distinct clinical and genetic associations. Using biological…
Abstract Number: 138 • 2017 Pediatric Rheumatology Symposium
Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis
Zihua Hu¹, Kaiyu Jiang², Mark B. Frank³, Yanmin Chen² and James Jarvis⁴, ¹Center for Computational Research, University at Buffalo, Buffalo, NY, ²Pediatrics, University at Buffalo, Buffalo, NY, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: We have previously shown that neutrophils in children with polyarticular juvenile idiopathic arthritis (JIA) display abnormal transcriptional patterns linked to fundamental metabolic derangements. These…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].